Si está buscando comprar medicamentos en línea en España, es importante elegir una farmacia en línea de confianza y segura para garantizar que los medicamentos que reciba sean auténticos y de alta calidad. En comprar-farmacia.es, ofrecemos una amplia selección de medicamentos, incluido Cialis para la disfunción eréctil (DE), y trabajamos con farmacias acreditadas para garantizar la calidad y la autenticidad de nuestros productos.
Visite nuestro sitio web en comprar-farmacia.es para obtener más información sobre nuestros productos y servicios. Nuestro equipo de atención al cliente está disponible para ayudarlo en todo momento y garantizar una experiencia de compra en línea segura y satisfactoria.
Untitled
Alizyme plc Interim Report 2004 ALIZYME plc | Interim Report 2004 Highlights
■ Revenues of £1.6 million (H1 2003: Nil)
■ Loss after tax £1.0 million (H1 2003: £7.1 million)
■ Cash and short term investments at 30 June 2004 of £20.6 million (2003: £15.4 million)
■ Renzapride (Irritable Bowel Syndrome)
Successful clinical trial in c-IBS patients at Mayo Clinic, USA
Initiated regulatory process with FDA for Phase III in USA
■ ATL-962 (Obesity and diabetes)
$3 million paid by Takeda to exercise rights to ATL-962 for Japan
Approval for Phase IIb clinical trial in obese diabetics (announced 27 September 2004)
Takeda submit IND for Phase I clinical trial in Japanese subjects
■ COLAL-PRED™ (Ulcerative colitis)
Initiated regulatory process with European authorities for Phase III in EU
Manufacturing development for Phase III and commercialisation
■ ATL-104 (Mucositis)
Commenced Phase IIa clinical trial in cancer patients
ALIZYME plc | Interim Report 2004 Chairman’s and Chief Executive’s statement
Chairman’s and Chief Executive’s statement
Overview
peak sales. Zelnorm® has also recently received
In the first half of 2004 we continued building on the
approval for an additional indication in the USA for the
excellent results achieved in 2003, making significant
treatment of chronic constipation in women under 65
progress with all four of our products in clinical
Renzapride, with its unique mode of action, has
Both renzapride (irritable bowel syndrome “IBS”) and
potential within the IBS market to treat not only c-IBS
COLAL-PRED™ (ulcerative colitis) are in preparation for
but also to be first line therapy for mixed symptom IBS
Phase III clinical trials. ATL-962 (obesity/type II diabetes)
(“m-IBS”). With m-IBS patients making up approximately
is about to commence its second Phase IIb clinical trial,
40% of the total IBS population, and with no other
and cancer patients are currently being recruited into
product either approved or in development for m-IBS, it
ATL-104’s (mucositis) Phase IIa clinical trial.
could provide renzapride with a substantial commercialopportunity.
Importantly, our portfolio of products is now at asufficiently late development stage that the products,
During the period we continued work in preparation for
and in particular renzapride and ATL-962, are being
renzapride’s entry into Phase III clinical development
increasingly recognised in the global pharmaceutical
including a number of preclinical and manufacturing
environment as potential competitive products.
activities in preparation for Phase III and registration. Our strong data package has also allowed us to initiate
With the two successful fundraisings in 2003 and
discussions with the FDA on the Phase III protocol
following the payment by Takeda of an additional
design for registration studies in the USA. We anticipate
$3 million in January, we have a strong cash position,
reaching agreement with the FDA around the end of the
with sufficient funds in our current plans to see us
year and commencing Phase III clinical development
beyond the end of 2006. Our financial position also
enables us to continue to negotiate from a position ofstrength in securing collaboration and partnering
Following on from the FDA approval we would anticipate
agreements for financing the late stage development of
entering into a collaboration to provide funding for the
RENZAPRIDE
In January 2004 we reported successful results from our
In January 2004, Takeda exercised its rights to a licence
clinical trial in constipation predominant IBS and development agreement relating to ATL-962 for(“c-IBS”) patients that was carried out at Mayo Clinic in
Japan. This followed their detailed review of the data
the USA. Data from this trial supported the findings from
from our successful European Phase IIb clinical trial in
our Phase IIb clinical trial in c-IBS patients that reported
clinically obese patients, announced in September 2003.
in 2003, demonstrating that renzapride enhances
As a result of this Takeda paid a further $3 million in
gastrointestinal motility and symptom relief, compared
addition to the $2 million in 2003. The agreement
provides for a further potential $37 million in milestonepayments and double digit royalties on sales in Japan.
The IBS market continues to develop. Since its launch in2002, Novartis’ product Zelnorm® approved in a number
The collaboration with Takeda is working extremely well.
of countries for the treatment of c-IBS in women, has
Takeda has progressed the preclinical development of
seen its sales increase quarter on quarter with the latest
ATL-962 in Japan and has submitted an IND with the
estimates in excess of $300 million for its second full
expectation of entering Phase I clinical development in
year of sales and projections approaching $1.5 billion for
ALIZYME plc | Interim Report 2004 Chairman’s and Chief Executive’s statement
Chairman’s and Chief Executive’s statement(continued)
We announced separately today approval to commence
product to Abbott’s product Meridia®. Both ATL-962 and
a Phase IIb clinical trial in clinically obese diabetic
Xenical® are lipase inhibitors and act locally in the gut
patients. The multi-centre trial, to be conducted in the
United Kingdom, with involvement of up to five otherEuropean countries, will enrol up to 600 clinically obese
In a recent report on the global obesity market
diabetic patients, with a Body Mass Index above 28,
published by Datamonitor, the prescription market for
whose diabetes is currently managed with the diabetic
obesity alone was forecast to be around $2.5 billion by
drug metformin. The objectives of the study are to
2012, of which it was anticipated that ATL-962 would be
determine the effect of ATL-962 on weight loss and its
the market leader, with sales of $945 million, and
safety and tolerability profile in these patients,
Acomplia® sales of $829 million, assuming both
compared to placebo and also to orlistat (Roche’s
products complete development and receive marketing
Xenical®). Trial results are expected to be reported
approval with the appropriate product profile.
around the end of 2005 and, if successful, willsignificantly increase the commercial opportunity forATL-962, allowing the potential expansion of the
COLAL-PREDTM
product labelling to cover not only clinically obese, but
The activity in the first half of the year has concentrated
also clinically obese diabetic patients.
on preparation for the Phase III registration clinical trialin Europe in patients with active ulcerative colitis. This
During the period, we carried out a number of preclinical
has included optimising the formulation, scaling up the
and manufacturing activities to facilitate Phase III
manufacturing process and validating in-process
development. In addition, in preparation for this current
controls for COLAL-PRED™. In addition we also
trial, Alizyme carried out a Phase I drug interaction study
undertook regulatory discussions in a number of
with metformin and ATL-962, to determine that
European countries and anticipate reaching agreement
ATL-962 does not adversely affect the therapeutic
for the design of the Phase III registration trial with
use of metformin. The results of this study also
European regulators before the end of the year. We
confirmed the acceptable safety and tolerability profile
would then expect to commence the Phase III clinical
of ATL-962 observed to date in the Phase Ib and Phase
trial in 2005 with results reported around the end of
The market for obesity management provides
Our cash position allows us to conduct this registration
substantial opportunity for an effective product with an
study using our own financial resources, whilst
acceptable side effect profile. During the period
continuing dialogue with a number of potential
GlaxoSmithKline signed an agreement with Roche with
commercialisation partners for COLAL-PRED™.
an initial payment of almost $100 million for the over-the-counter (‘OTC’) rights to Roche’s product Xenical®. This agreement further demonstrates the demand for effective products in the area of obesity and
weight management and the value ascribed to such
The Phase IIa proof of concept clinical trial in cancer
patients was initiated in the period and continues torecruit patients. We expect to be in a position to report
The sanofi-aventis Group currently has a product,
the results from this trial around the middle of 2005.
Acomplia®, in Phase III development for the
Given successful results, we believe that further
management of obesity and smoking cessation. The
investment in ATL-104 would be justified and we will
mode of action for Acomplia® is a centrally acting,
assess the most optimum route for the further
appetite suppressant and is likely to be a competitive
ALIZYME plc | Interim Report 2004 Chairman’s and Chief Executive’s statement Financial Review
In the six months ended 30 June 2004, Alizyme made a
As we move forward, over the next 12 months, we
net loss of £1.0 million (2003: £7.1 million). Cash
anticipate a number of value enhancing events which
outflow before management of liquid resources and
would continue the transformation of the profile of
financing, for the period was £1.8 million (2003:
£5.0 million). Cash and short-term investments were£20.6 million at 30 June 2004 (£15.4 million at
Reaching agreement with both European and US
regulatory authorities on the Phase III designs of COLAL-PRED™ and renzapride respectively, will be very
In January Takeda paid £1.6 million following their
important in validating these products’ development to
exercise of rights to a licence and development
date as well as opening up the potential route to market
agreement relating to ATL-962 for Japan. This income
and commercialisation. In turn this will also facilitate
has been recognised in full in the period.
collaborations allowing Alizyme to access the financialsupport necessary to complete development and
Research and development expenditure was significantly
lower at £2.9 million (2003: £7.3 million), reflecting alower level of clinical trial activity than the
We also look forward to substantive clinical data from
corresponding period in 2003. Management and
the ATL-962 Phase IIb trial in clinically obese diabetics
administration expenses at £0.5 million remained the
and the first proof of principle data from the ATL-104
The low level of net loss in the period exemplifies the
The team at Alizyme has again made a significant
leverage of the Alizyme outsourcing business model,
contribution to the achievements in the period and we
and provides a powerful indication of how future
take this opportunity to thank everyone for their
revenues, combined with a controlled but effective
spend on development, could have a dramaticallypositive effect on the financial performance of theCompany.
It is anticipated that the second half of 2004 will showR&D expenditure slightly higher than reported in the
Sir Brian Richards CBE
first half, with the main activities being the continued
Chairman
recruitment into the Phase IIa ATL-104 clinical trial incancer patients and commencement of recruitment intothe Phase IIb ATL-962 clinical trial in obese diabetics.
Following the two successful fundraisings that werecompleted in 2003, Alizyme continues to retain a strong
Dr Richard Palmer
cash position with sufficient funds to complete the
Chief Executive Officer
planned Phase III European clinical trial of COLAL-PRED™, the Phase IIb European clinical trial of ATL-962in obese diabetics and the ongoing Phase IIa UK clinical
27 September 2004 ALIZYME plc | Interim Report 2004 Consolidated Profit and Loss Account
Consolidated Profit and Loss AccountFor the six months ended 30 June 2004
Six months Six months Twelve months 31 December £000’s £000’s £000’s Turnover Operating expenses: Operating loss Loss on ordinary activities before taxation Loss for the period being the retained loss for the period attributable to the members of Alizyme plc Loss per share – basic and diluted
There were no recognised gains and losses in any period other than the retained loss for that period.
All amounts relate to continuing activities.
The accompanying notes form an integral part of this Consolidated Profit and Loss Account. ALIZYME plc | Interim Report 2004 Consolidated Balance Sheet
Consolidated Balance SheetAs at 30 June 2004
31 December £000’s £000’s £000’s Fixed assets Current assets Creditors: Amounts falling due within one year Net current assets Total assets less current liabilities Provisions for liabilities and charges Net assets Capital and reserves Equity shareholders’ funds
The accompanying notes form an integral part of this Consolidated Balance Sheet. ALIZYME plc | Interim Report 2004 Consolidated Cash Flow Statement
Consolidated Cash Flow StatementFor the six months ended 30 June 2004
Six months Six months Twelve months 31 December £000’s £000’s £000’s Net cash outflow from operating activities Returns on investments and servicing of finance Net cash inflow from returns on investments and servicing of finance Taxation
Research and development tax credit received
Net cash inflow from taxation Capital expenditure and financial investment Net cash outflow from capital expenditure and financial investment Cash outflow before management of liquid resources and financing Management of liquid resources Net cash inflow/(outflow) from management of liquid resources Financing
Issue of ordinary share capital (net of expenses)
Net cash inflow from financing Increase/(decrease) in cash in the period
The accompanying notes form an integral part of this Consolidated Cash Flow Statement. ALIZYME plc | Interim Report 2004 Notes to the financial information
Notes to the financial informationUnaudited1. Basis of preparation The interim financial information has been prepared on the basis of the accounting policies set out in the Group’s statutory financial statements for the year ended 31 December 2003.
These interim financial statements do not constitute statutory financial statements within the meaning of section240 of the Companies Act 1985. Results for the six month periods ended 30 June 2004 and 30 June 2003 have notbeen audited. The results for the year ended 31 December 2003 have been extracted from the statutory financialstatements, which have been filed with the Registrar of Companies and upon which the auditors reported withoutqualification.
Copies of the interim results for the six months ended 30 June 2004 are being sent to all shareholders. Details canalso be found on the Company’s website at www.alizyme.com. Further copies of the interim results and copies ofthe full financial statements for the year ended 31 December 2003 can be obtained by writing to the CompanySecretary, at Alizyme plc, Granta Park, Great Abington, Cambridge CB1 6GX or by sending an electronic mail [email protected]. 2. Loss per share Loss per share is based on the loss of £974,000 for the six months ended June 2004 (six months ended June 2003 – £7,112,000; twelve months ended December 2003 – £10,008,000) and on 144,391,000 ordinary shares (June 2003 – 120,821,000; December 2003 – 130,476,000) being the weighted average number of equity shares in issue during the period.
The diluted loss per share takes into account the dilutive effect of share options. Ordinary shares which arepotentially issuable are only included in the calculation of diluted earnings per share if their issue would decreasenet profit per share or increase net loss per share. The exercise of share options does not increase the basic lossper share and therefore the basic and diluted loss per share remain the same. 3. Provision for employer’s National Insurance on gains on share options In accordance with Urgent Issues Task Force abstract 25 (“National Insurance contributions on share option gains”) the Group has recognised a provision of £181,000 (30 June 2003 – £64,000; 31 December 2003 – £279,000) for National Insurance contributions that will be payable on gains realised upon the future exercise of share options issued. The provision calculation is based upon the closing share price of the Company on 30 June 2004, which was 130.5p (30 June 2003 – 48p; 31 December 2003 – 173p) and calculated at a National Insurance rate of 12.8% (30 June 2003 – 12.8%; 31 December 2003 – 12.8%). Any provision is allocated over the performance period of each employee, where the performance period is the period during which the employee must perform the services necessary to become unconditionally entitled to the options. 4. Reconciliation of operating loss to operating cash flows Six months Six months Twelve months 31 December £000’s £000’s £000’s Net cash outflow from operating activities ALIZYME plc | Interim Report 2004 Independent review report to Alizyme plc Introduction We have been instructed by the Company to review the financial information for the six months ended 30 June 2004, which comprises the profit and loss account, the balance sheet, the cash flow statement and related notes 1 to 4. We have read the other information contained in the interim report and considered whether it contains any apparent misstatements or material inconsistencies with the financial information.
This report is made solely to the Company in accordance with Bulletin 1999/4 issued by the Auditing PracticesBoard. Our work has been undertaken so that we might state to the Company those matters we are required tostate to them in an independent review report and for no other purpose. To the fullest extent permitted by law,we do not accept or assume responsibility to anyone other than the Company, for our review work, for thisreport, or for the conclusions we have formed. Directors’ responsibilities The interim report, including the financial information contained therein, is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the interim report in accordance with the Listing Rules of the Financial Services Authority which require that the accounting policies and presentation applied to the interim figures should be consistent with those applied in preparing the preceding annual accounts except where any changes, and the reasons for them, are disclosed. Review work performed We conducted our review in accordance with the guidance contained in Bulletin 1999/4 issued by the Auditing Practices Board for use in the United Kingdom. A review consists principally of making enquiries of group management and applying analytical procedures to the financial information and underlying financial data and, based thereon, assessing whether the accounting policies and presentation have been consistently applied unless otherwise disclosed. A review excludes audit procedures such as tests of controls and verification of assets, liabilities and transactions. It is substantially less in scope than an audit performed in accordance with United Kingdom auditing standards and therefore provides a lower level of assurance than an audit. Accordingly, we do not express an audit opinion on the financial information. Review conclusion On the basis of our review we are not aware of any material modifications that should be made to the financial information as presented for the six months ended 30 June 2004. Deloitte & Touche LLP Chartered Accountants Cambridge
For further information, please contact:Dr Richard Palmer, Chief Executive OfficerTim McCarthy, Finance DirectorALIZYME plcT +44 (0) 1223 896000F +44 (0) 1223 896001
ALIZYME plc Granta Park Great Abington Cambridge CB1 6GX United Kingdom
T +44 (0) 1223 896000F +44 (0) 1223 896001
L’ANTICONCEPCIÓ D’EMERGÈNCIA AMB LEVONORGESTREL A LES OFICINES DE FARMÀCIA DISPENSACIÓ SENSE PRESCRIPCIÓ MÈDICA Generalitat de Catalunya Departament de Salut L’ANTICONCEPCIÓ D’EMERGÈNCIA AMB LEVONORGESTREL A LES OFICINES DE FARMÀCIA 1. Introducció 2. Indicació de l’anticoncepció d’emergència 3. Accés a l’anticoncepció d’emergència 4. Pr
SCHEDULING STATUS: PROPRIETARY NAME: PANADO AND DOSAGE FORM (Tablets) COMPOSITION: Each tablet contains 500 mg paracetamol. Sugar free PHARMACOLOGICAL CLASSIFICATION: A 2.7 Antipyretics or antipyretic and anti-inflammatory analgesics PHARMACOLOGICAL ACTION: Paracetamol has analgesic and antipyretic properties. It acts predominantly by inhibiting prostaglandi